Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jihane AOUNI"'
Publikováno v:
Bone Marrow Transplantation. 57:1827-1832
Plerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34+ (CD34+) cells in the peripheral blood (PB) approximatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55406b8be4c74b8963738ecf543d2c89
https://doi.org/10.1038/s41409-022-01831-2
https://doi.org/10.1038/s41409-022-01831-2
Publikováno v:
Statistics in Medicine. 40:566-577
The Matching-Adjusted Indirect Comparison method (MAIC) is a recent methodology that allows to perform indirect comparisons between two drugs assessed in two different studies, where individual patients data are available in only one of the two studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c1265237b74056965f140f36296753
https://doi.org/10.1002/sim.8789
https://doi.org/10.1002/sim.8789
Publikováno v:
Therapeutic Innovation & Regulatory Science
Therapeutic Innovation & Regulatory Science, 2021, 55, pp.818-840. ⟨10.1007/s43441-021-00273-0⟩
Therapeutic Innovation & Regulatory Science, Springer, 2021, 55, ⟨10.1007/s43441-021-00273-0⟩
Therapeutic Innovation & Regulatory Science, 2021, 55, pp.818-840. ⟨10.1007/s43441-021-00273-0⟩
Therapeutic Innovation & Regulatory Science, Springer, 2021, 55, ⟨10.1007/s43441-021-00273-0⟩
Dose selection is a key feature of clinical development. Poor dose selection has been recognized as a major driver of development failure in late phase. It usually involves both efficacy and safety criteria. The objective of this paper is to develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fd2d5e2aede6cfb743db9b9d704683
https://inria.hal.science/hal-02491551
https://inria.hal.science/hal-02491551
Publikováno v:
Therapeutic innovationregulatory science. 55(4)
Dose selection is a key feature of clinical development. Poor dose selection has been recognized as a major driver of development failure in late phase. It usually involves both efficacy and safety criteria. The objective of this paper is to develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60d38c695e074b923fd4657ed55c7280
https://pubmed.ncbi.nlm.nih.gov/33851358
https://pubmed.ncbi.nlm.nih.gov/33851358
Autor:
Pierre Colin, Bernard Sebastien, Jean Noel Bacro, Gwladys Toulemonde, Loic Darchy, Jihane Aouni
Publikováno v:
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics, Taylor & Francis, 2020, 30 (4), pp.662-673. ⟨10.1080/10543406.2020.1730874⟩
Journal of Biopharmaceutical Statistics, 2020, 30 (4), pp.662-673. ⟨10.1080/10543406.2020.1730874⟩
Journal of Biopharmaceutical Statistics, Taylor & Francis, 2020, 30 (4), pp.662-673. ⟨10.1080/10543406.2020.1730874⟩
Journal of Biopharmaceutical Statistics, 2020, 30 (4), pp.662-673. ⟨10.1080/10543406.2020.1730874⟩
International audience; Dose selection is one of the most difficult and crucial decisions to make during drug development. As a consequence the dose-finding trial is a major milestone in the drug development plan and should be properly designed. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb55b837a83f1ebd404a0e693fb8bf75
https://hal.inria.fr/hal-03082449
https://hal.inria.fr/hal-03082449
Autor:
Jihane AOUNI, Jean Noel BACRO, Gwladys TOULEMONDE, Pierre COLIN, Loic DARCHY, Bernard SEBASTIEN
Publikováno v:
Biostatistiques et sciences de la santé. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8a100a5e32a75a4e7d038e4b31985ef
https://doi.org/10.21494/iste.op.2019.0397
https://doi.org/10.21494/iste.op.2019.0397